Interactive Strength Inc. (Nasdaq:TRNR) Enters into $500 Million Facility to Acquire AI-focused $FET Tokens and Launch Crypto Treasury Asset Strategy

TRNR enters into technology collaboration with Fetch.ai to power its fitness training with AI technology
AUSTIN, TX / ACCESS Newswire Interactive Strength Inc. (Nasdaq:TRNR), maker of innovative specialty fitness equipment under the CLMBR and FORME brands and pending acquirer of Sportstech and Wattbike, today announced that it has entered into a Securities Purchase Agreement to raise up to $500 million, the net proceeds of which are expected to be used exclusively to acquire $FET tokens, a leading AI digital asset developed by Fetch.ai.
This transaction is expected to result in TRNR having the largest publicly-listed crypto treasury focused on an AI-token. TRNR is already in the process of acquiring $FET tokens with the initial $55 million of new capital that has been invested by private equity firm ATW Partners and crypto market-maker DWF Labs.
'Digital assets are rapidly becoming an essential part of global financial infrastructure and AI is the biggest technological leap in our lifetimes,' said Trent Ward, CEO of TRNR. 'Fetch.ai is the market leader at the intersection of the two most important technology trends today: artificial intelligence and crypto. We believe our strategy to acquire a significant number of $FET tokens could dramatically accelerate our mission to create significant long-term value for TRNR shareholders.'
'We are proud to support this landmark deal, advancing institutional crypto adoption,' said Andrei Grachev, Managing Partner of DWF Labs. 'As a global leader in crypto investments and market making, we see enormous potential in TRNR's treasury strategy and Fetch.ai's vision, signaling the next wave of corporate capital markets embracing AI-driven digital assets.'
'Unlike traditional models that generate isolated responses, Fetch.ai's ecosystem is built on autonomous agents that can interact, collaborate, and transact in real time,' said Humayun Sheikh, CEO of Fetch.ai. 'This enables users to build and monetize AI tools that operate independently -whether for booking doctor appointments, market forecasting, or personalized fitness plans.'
Fetch.ai's platform features the world's first decentralized LLM designed for autonomous action, not just content generation, and powers AI agents that optimize critical industries – from medical research and energy to logistics and finance. Fetch.ai is the original issuer of $FET and a member of the Artificial Superintelligence Alliance (ASI). As part of the deal, Fetch.ai will collaborate with TRNR to expand its digital fitness services into, e.g., an AI-driven personal training platform.
This investment accelerates TRNR's momentum from its two pending acquisitions, which TRNR believes highlights the strong institutional investor support for the Company's strategy of combining crypto treasury assets and accretive acquisitions. The crypto treasury asset strategy is expected to strengthen TRNR's financial flexibility, as well as support its AI and digital fitness ambitions, and increase shareholder exposure to next-generation growth assets.
$FET is a top-50 cryptocurrency and a top-5 AI-focused cryptocurrency by market capitalization according to coinmarketcap.com.
TRNR will leverage BitGo for both the trading and custody of its $FET holdings through BitGo's best-in-class custody platform.
Advisors:
Legal advisors included Lucosky Brookman (Interactive Strength), K&L Gates/Ed Dartley (Fetch.ai), Kelly Drye & Warren (ATW Partners), Blank Rome (ATW Partners) and Nixon Peabody (DWF Labs). Wachsman is the communications and strategy firm for the transaction and the agency of record for Fetch.ai.
For more commentary, information and details on the rationale for and structure of the expected acquisition, please see TRNR's investor website as well as its required filings with the U.S. Securities and Exchange Commission (SEC).
Fetch.ai Media Contact
Fetch.ai@wachsman.com
TRNR Media Contact
john@sintercompany.com
TRNR Investor Contact
ir@interactivestrength.com
About Fetch.ai:
Fetch.ai Inc. is a Delaware-based AI company and founding member of the ASI Alliance, is redefining the possibilities of an intelligent and connected world through its AI agent-based technology. Fetch.ai's infrastructure technology enables developers and businesses to build, deploy and monetize through an agent-based modular platform for the new generation of AI applications. The company's core product, Agentverse, fuses Language Models (LLMs) and AI Agents to create an open and dynamic marketplace that connects users to services and reimagines the current search experience. For additional information, visit: Fetch.ai.
About Interactive Strength Inc.:
Interactive Strength Inc. produces innovative specialty fitness equipment and digital fitness services under two main brands: 1) CLMBR and 2) FORME. Interactive Strength Inc. is listed on NASDAQ (symbol:TRNR). CLMBR is a vertical climbing machine that offers an efficient and effective full-body strength and cardio workout. CLMBR's design is compact and easy to move – making it perfect for commercial or in-home use. With its low impact and ergonomic movement, CLMBR is safe for most ages and levels of ability and can be found at gyms and fitness studios, hotels, and physical therapy facilities, as well as available for consumers at home. www.clmbr.com.
FORME is a digital fitness platform that combines premium smart gyms with live virtual personal training and coaching to deliver an immersive experience and better outcomes for both consumers and trainers. FORME delivers an immersive and dynamic fitness experience through two connected hardware products: 1) The FORME Studio Lift (fitness mirror and cable-based digital resistance) and 2) The FORME Studio (fitness mirror). In addition to the company's connected fitness hardware products, FORME offers expert personal training and health coaching in different formats and price points through Video On-Demand, Custom Training, and Live 1:1 virtual personal training. www.formelife.com.
Channels for Disclosure of Information
In compliance with disclosure obligations under Regulation FD, we announce material information to the public through a variety of means, including filings with the Securities and Exchange Commission ('SEC'), press releases, company blog posts, public conference calls, and webcasts, as well as via our investor relations website. Any updates to the list of disclosure channels through which we may announce information will be posted on the investor relations page on our website. The inclusion of our website address or the address of any third-party sites in this press release are intended as inactive textual references only.
Forward Looking Statements:
This press release includes certain statements that are 'forward-looking statements' for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and reflect management's assumptions, views, plans, objectives and projections about the future. Forward-looking statements generally are accompanied by words such as 'believe', 'project', 'expect', 'anticipate', 'estimate', 'intend', 'strategy', 'future', 'opportunity', 'plan', 'may', 'should', 'will', 'would', 'will be', 'will continue', 'will likely result' or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the possibility of acquiring future businesses or completing the referenced pending transactions in a timely manner or at all, the ultimate gross proceeds of the financing, the Company having the largest US publicly listed crypto treasury focused on an AI-token, and the financing strengthening the Company's financial flexibility, supporting the Company's AI and digital fitness ambitions, and increasing shareholder exposure to next-generation growth assets. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Risks and uncertainties include but are not limited to: whether ATW Partners and / or DWF Labs will invest further amounts, other US publicly listed companies' crypto strategies, and the price of $FET tokens. A further list and descriptions of these risks, uncertainties and other factors can be found in filings with the Securities and Exchange Commission. To the extent permitted under applicable law, the Company assumes no obligation to update any forward-looking statements.
# # #
SOURCE: Interactive Strength Inc.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

傳蘋果將捨棄Google合作 將收購AI搜尋黑馬Perplexity

科技中心／李宜樺報導 ▼▲蘋果傳新併購消息！恐捨棄Google，轉密會AI搜尋新星Perplexity。（圖／翻攝自YT@Apple） AI戰升溫，科技巨頭火力全開！繼Meta投資Scale AI後，如今傳出蘋果也悄悄布局，要收購AI搜尋新貴「Perplexity AI」，甚至傳出考慮放棄Google作為預設搜尋引擎。這場看似平靜的搜尋戰場，已悄然掀起風暴！ 根據《彭博》知名科技記者Mark Gurman爆料，蘋果併購部門主管Adrian Perica已在內部討論是否收購Perplexity，雖仍處於早期階段，但若交易成真，將是蘋果史上最大規模併購案──該公司估值高達140億美元，遠超2014年30億美元收購Beats的紀錄。 除了併購，蘋果也考慮另一合作模式，將Perplexity整合至Safari與Siri，作為替代Google搜尋的AI解決方案。畢竟蘋果與Google的搜尋合作協議，正面臨美國反壟斷調查威脅，恐有被迫拆夥的可能。 Perplexity成立僅兩年，卻以AI驅動搜尋技術嶄露頭角，透過自動總結、引文標示等功能挑戰Google霸主地位，甚至已與三星展開深度合作，成為蘋果收購計畫的潛在障礙。 Perplexity對收購傳聞低調回應，稱「目前沒有相關消息」，但該公司近期與多家科技巨頭接觸頻繁，包括Meta也曾試圖收購、並挖角其CEO Aravind Srinivas，顯示AI搜尋市場人才爭奪戰已進入白熱化。 當AI搜尋成為下一代搜尋引擎的競爭主戰場，蘋果此舉無疑是對Google發出重大威脅。科技巨頭的版圖重組已開始，誰能掌握搜尋流量與AI技術，誰就能主宰未來。 更多三立新聞網報導2025報稅必知／報稅倒數9天 你真的報完了嗎？「這一步」沒做＝白報！美軍參戰 介入以伊戰爭！衝突升級 冷靜異常的黃金現補漲行情？全球熱錢瘋搶亞洲 高盛曝對沖基金5年最大買盤新光金、新壽5月再虧破百億 靠準備金撐盤仍難止血？

Yahoo

an hour ago

• Yahoo

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveTree-selected targets addressing oncology, autoimmune disorders, and neurological diseases. Pursuant to the LOI, XtalPi will receive an upfront payment of $51 million within 10 days of executing the definitive agreement and an additional $49 million within 180 days. Subject to final agreement terms, XtalPi is also eligible to receive potential development and commercial milestone payments exceeding $10 billion, as well as tiered, single-digit royalties on annual net product sales. DoveTree will obtain exclusive global development and commercialization rights to the resulting therapeutics. Professor Gregory Verdine, the Erving Professor of Chemistry at Harvard University, is a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed to Harvard's faculty at age 29, he became the Chemistry Department's youngest tenured professor in nearly five decades at 35. He has elucidated the molecular mechanism of epigenetic DNA methylation and revealed the pathways by which certain genotoxic forms of DNA damage are identified and eradicated. He is a leading figure in the field of new therapeutic modalities, and has developed of a new class of therapeutics termed stapled peptides, enabling drug development against targets long considered undruggable. As an entrepreneurial leader, Professor Verdine has founded or co-founded over ten biotechnology companies, including five publicly listed entities: Enanta Pharmaceuticals (NASDAQ: ENTA), Tokai Pharmaceuticals (NASDAQ: TKAI), and Wave Life Sciences (NASDAQ: WVE), among others. One venture was acquired by a major pharmaceutical company, while others continue developing disruptive medicines with a special focus on oncology. Three therapeutics he spearheaded—romidepsin (Istodax®), paritaprevir (a component of Viekira Pak®), and glecaprevir (a component of Mavyret®) —have received FDA approval. Professor Verdine currently serves as a Venture Partner at Andreessen Horowitz (a16z), a role he previously held at Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures. He was also a Special Advisor to Texas Pacific Group. His advisory engagements include top research institutions such as the U.S. National Cancer Institute and Harvard Medical School. "By integrating XtalPi's cutting-edge AI capabilities with decades of drug development expertise, we have a unique opportunity to deliver transformative therapies to patients worldwide," stated Professor Verdine. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc.

Yahoo

an hour ago

• Yahoo

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveTree-selected targets addressing oncology, autoimmune disorders, and neurological diseases. Pursuant to the LOI, XtalPi will receive an upfront payment of $51 million within 10 days of executing the definitive agreement and an additional $49 million within 180 days. Subject to final agreement terms, XtalPi is also eligible to receive potential development and commercial milestone payments exceeding $10 billion, as well as tiered, single-digit royalties on annual net product sales. DoveTree will obtain exclusive global development and commercialization rights to the resulting therapeutics. Professor Gregory Verdine, the Erving Professor of Chemistry at Harvard University, is a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed to Harvard's faculty at age 29, he became the Chemistry Department's youngest tenured professor in nearly five decades at 35. He has elucidated the molecular mechanism of epigenetic DNA methylation and revealed the pathways by which certain genotoxic forms of DNA damage are identified and eradicated. He is a leading figure in the field of new therapeutic modalities, and has developed of a new class of therapeutics termed stapled peptides, enabling drug development against targets long considered undruggable. As an entrepreneurial leader, Professor Verdine has founded or co-founded over ten biotechnology companies, including five publicly listed entities: Enanta Pharmaceuticals (NASDAQ: ENTA), Tokai Pharmaceuticals (NASDAQ: TKAI), and Wave Life Sciences (NASDAQ: WVE), among others. One venture was acquired by a major pharmaceutical company, while others continue developing disruptive medicines with a special focus on oncology. Three therapeutics he spearheaded—romidepsin (Istodax®), paritaprevir (a component of Viekira Pak®), and glecaprevir (a component of Mavyret®) —have received FDA approval. Professor Verdine currently serves as a Venture Partner at Andreessen Horowitz (a16z), a role he previously held at Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures. He was also a Special Advisor to Texas Pacific Group. His advisory engagements include top research institutions such as the U.S. National Cancer Institute and Harvard Medical School. "By integrating XtalPi's cutting-edge AI capabilities with decades of drug development expertise, we have a unique opportunity to deliver transformative therapies to patients worldwide," stated Professor Verdine. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data